

Alexey Ansheles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676576/publications.pdf>

Version: 2024-02-01

31
papers

94
citations

1937685
4
h-index

1588992
8
g-index

39
all docs

39
docs citations

39
times ranked

57
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of the clinical appearance, laboratory measures and scintigraphy data in patients with different types of primary and secondary hyperparathyroidism. <i>ÂndokrinologiÂ Novosti, MneniÂ, ObuÂenie</i> , 2022, 11, 24-32.	0.2	1
2	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). <i>Terapevticheskii Arkhiv</i> , 2022, 94, 584-595.	0.8	9
3	Myocardial scintigraphy with ^{99m}Tc -pyrophosphate in the diagnosis of cardiac amyloidosis: place in the diagnostic algorithm, features of the implementation and interpretation of the study. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 530-537.	0.8	0
4	The Role of Scintigraphy and Hybrid Single-Photon Emission Tomography in Comparison with Laboratory Data in a Comprehensive Examination of Patients with Secondary Hyperparathyroidism. <i>Vestnik Rentgenologii I Radiologii</i> , 2022, 103, 15-29.	0.2	0
5	Impact of the first wave of coronavirus disease 2019 (COVID-19) pandemic on the diagnosis of heart disease in the Russian Federation: results from the IAEA Nuclear Cardiology Protocols Study (INCAPS). <i>Russian Journal of Cardiology</i> , 2021, 26, 4276.	1.4	4
6	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020). <i>Eurasian Heart Journal</i> , 2021, , 6-43.	0.8	20
7	Relationship of obesity, low-density lipoprotein cholesterol and myocardial perfusion in patients with risk factors and without atherosclerotic cardiovascular diseases. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2734.	1.4	2
8	Nuclear imaging of chemotherapy-induced cardiotoxicity. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2537.	1.4	1
9	Mobile application "Aterostop" for a comprehensive assessment of cardiovascular risk in patients in the Russian population. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 415-420.	0.8	2
10	Nuclear medicine and molecular imaging in clinical practice: yesterday, today and tomorrow. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 357-362.	0.8	1
11	Possibilities of Evaluating the Dynamics of Left Ventricular Perfusion and Contractility in Patients with Chronic Heart Failure after Implantation of a Heart Contractility Modulator Using Perfusion Single-Photon Emission Computed Tomography. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 263-269.	0.8	0
12	Left ventricular myocardial cellular perfusion against the background of cardiac contractility modulation in patients with heart failure and atrial fibrillation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4238.	1.4	0
13	Interpretation of myocardial perfusion SPECT with attenuation correction. Part 2. <i>Vestnik Rentgenologii I Radiologii</i> , 2020, 101, 6-18.	0.2	2
14	Current state of the problem of pretest probability assessment of ischemic heart disease. <i>Vestnik Nacional'noġo Mediko-hirurgiÂeskogo Centra Im N I Pirogova</i> , 2020, 15, 124-132.	0.1	2
15	Mathematical Modeling of Myocardial Perfusion Diagnosed by the Method of Single-Photon Emission Computed Tomography. <i>Technical Physics</i> , 2020, 65, 1436-1441.	0.7	0
16	ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 90-98.	0.8	7
17	A study of false apical defects in myocardial perfusion imaging with SPECT/CT. <i>Biomedical Physics and Engineering Express</i> , 2018, 4, 065018.	1.2	6
18	NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 94-100.	0.8	3

#	ARTICLE	IF	CITATIONS
19	IDENTIFICATION OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN THE RUSSIAN POPULATION USING THE EXAMPLE OF MOSCOW CITY AND MOSCOW REGION. Rational Pharmacotherapy in Cardiology, 2018, 14, 77-87.	0.8	1
20	Current State and Future Technologies of Nuclear Imaging in Cardiology. Kardiologiya, 2018, 17, 61-69.	0.7	4
21	NUCLEAR IMAGING IN SUDDEN CARDIAC DEATH RISK ASSESSMENT. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 68-74.	1.4	1
22	MYOCARDIAL PERFUSION AND NEUROTROPIC SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY FEATURES IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION. Vestnik Rentgenologii I Radiologii, 2018, 99, 244-252.	0.2	4
23	Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of Experimental Biology and Medicine, 2017, 163, 133-136.	0.8	4
24	Interrelation of proprotein convertase subtilisin/pepsin 9 type level with carotid atherosclerosis severity in patients with hypercholesterolemia. Atherosclerosis, 2017, 263, e199.	0.8	0
25	Domestic Development of Single-Photon Emission Computed Tomography (SPECT) Unit with Detector based on Silicon Photomultipliers. Journal of Physics: Conference Series, 2017, 784, 012017.	0.4	0
26	NEUROTROPIC MYOCARDIAL SCINTIGRAPHY IN THE EVALUATION OF SUDDEN CARDIAC DEATH PROGNOSIS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY. Vestnik Rentgenologii I Radiologii, 2017, 98, 177-184.	0.2	1
27	Preliminary results of Russian familial hypercholesterolemia registry. Atherosclerosis, 2016, 252, e34-e35.	0.8	1
28	MYOCARDIAL PERFUSION SPECT WITH CT-BASED ATTENUATION CORRECTION: DATA ACQUISITION AND INTERPRETATION (GUIDELINES). Diagnostic Radiology and Radiotherapy, 2016, , 87-101.	0.2	3
29	Standardization of 123I-metaiodobenzylguanidine cardiac neurotropic scintigraphy and single-photon emission tomography. Vestnik Rentgenologii I Radiologii, 2016, , 173-180.	0.2	3
30	NEW APPROACH OF QUANTITATIVE NUCLEAR CARDIAC PERFUSION ASSESSMENT IN PATIENTS WITH PULMONARY HYPERTENSION. Vestnik Rentgenologii I Radiologii, 2016, 97, 340-347.	0.2	2
31	Radio nuclide diagnostics with neurotropic pharmaceuticals. , 2013, , .		0